---
layout: default
title: Felodipine
parent: 僅模型預測 (L5)
nav_order: 255
evidence_level: L5
indication_count: 7
---

# Felodipine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **7** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# FELODIPINE: From Hypertension to Pulmonary Hypertension with Unclear Multifactorial Mechanism

## One-Sentence Summary

Felodipine is a dihydropyridine calcium channel blocker (CCB) originally used to treat hypertension. The TxGNN model's top-ranked prediction suggests possible efficacy in **pulmonary hypertension with unclear multifactorial mechanism**, but this direction currently has **0 clinical trials** and **0 publications** supporting it — it is a model-score-only signal.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Hypertension (based on felodipine's known pharmacological classification as a dihydropyridine CCB; no formal Saudi Arabia label text is available since the drug is not marketed there) |
| Predicted New Indication | Pulmonary hypertension with unclear multifactorial mechanism |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 (no clinical trials or literature identified) |
| Saudi Arabia Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for felodipine is not available (DrugBank MOA field is a data gap). Based on known pharmacological classification, felodipine is a dihydropyridine calcium channel blocker used for hypertension, acting by inhibiting voltage-gated calcium influx into vascular smooth muscle to produce vasodilation.

The predicted indication itself — "pulmonary hypertension with unclear multifactorial mechanism" — is, by its own name, a disease category whose pathophysiology is not well defined (analogous to WHO Group 5 pulmonary hypertension). This ambiguity makes it difficult to construct a concrete pharmacological rationale connecting felodipine's calcium-channel-blocking activity to this specific condition.

No clinical trials or literature were retrieved for this drug-disease pair, and the evidence pack's own rationale explicitly flags this as a low-confidence, evidence-free prediction. This should be treated as a raw model signal rather than a substantiated repurposing hypothesis.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Saudi Arabia Market Information

Felodipine is not currently marketed in Saudi Arabia; no authorization records are available.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This is a rank-1 TxGNN score with no supporting clinical trials or literature, and the target indication's own mechanism is described as "unclear/multifactorial," preventing any concrete mechanistic linkage to felodipine. A Blocking-severity data gap also exists for TFDA/local regulatory warnings and contraindications, which precludes even a preliminary (S1) safety screen.

**To proceed, the following is needed:**
- Felodipine mechanism of action (MOA) data from DrugBank (currently a data gap, High severity)
- Official package insert / regulatory warnings and contraindications (currently a Blocking data gap — required before any S1 safety evaluation)
- A broader literature/trial search strategy for this indication, since the exact disease term returned zero hits
- Note: within this same evidence pack, the rank-7 candidate (Prinzmetal angina) shows a substantially stronger signal — 8 relevant publications including 3 RCTs specific to felodipine, evidence level L2, and a "Proceed with Guardrails" recommendation at decision stage S3. If the goal is to identify a viable repurposing candidate for felodipine, that indication warrants separate, prioritized evaluation rather than this rank-1 prediction.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

